Ascletis Reports Positive Preclinical Data for Oral Peptide Pipeline

The company reported half-lives of about 7–8.8 days and oral bioavailability of at least 6% in nonhuman primates. Its U.S. Phase I study of ASC36o has started, with topline pharmacokinetic data expected by end-2026.